Premium
Performance of serum galactomannan in patients with allergic bronchopulmonary aspergillosis
Author(s) -
Agarwal Ritesh,
Aggarwal Ashutosh N.,
Sehgal Inderpaul S.,
Dhooria Sahajal,
Behera Digambar,
Chakrabarti Arunaloke
Publication year - 2015
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12334
Subject(s) - galactomannan , allergic bronchopulmonary aspergillosis , medicine , gastroenterology , asthma , aspergillosis , area under the curve , confidence interval , immunology , immunoglobulin e , antibody
Summary Few studies have evaluated the performance of serum galactomannan (GM) in patients with allergic bronchopulmonary aspergillosis ( ABPA ). Herein, we analyse the diagnostic performance of serum GM in ABPA . Consecutive subjects with ABPA and asthma underwent GM estimation using the Platelia assay (Bio‐Rad Laboratories). An optical density index of >0.5 was considered positive. One hundred and twenty subjects (70 ABPA , 50 asthma) with a mean ( SD ) age of 33.0 (13.1) were included in the study. The serum GM antigen was positive in 18 (25.7%) subjects with ABPA compared to 9 (18%) subjects with asthma without ABPA ( P = 0.32). The sensitivity of the serum GM antigen test in patients with ABPA was 25.7% [95% confidence intervals ( CI ), 16–38] while the specificity was 82% (95% CI , 69–91). The positive and negative predictive values were 66.7% (95% CI , 46–84%) and 44.1% (95% CI , 34–55), respectively. The area under the ROC curve was 0.54 (95% CI , 0.44–0.64). The sensitivity increased and the specificity decreased with decreasing the serum GM cutoff, and vice versa. The results of this study suggest that serum GM estimation has a limited role in the diagnostic workup of patients with ABPA .